Endobronchial ultrasound in diagnosing and staging of Lung cancer22 G TBNB vs 22 G TBNA needles; a randomized controlled trial: EBUS Acquire?? Needle Trial
Recruiting
- Conditions
- ungcancer and mediastinal staging
- Registration Number
- NL-OMON20056
- Lead Sponsor
- Boston Scientific
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 120
Inclusion Criteria
(suspected) NSCLC/SCLC
-Indication for mediastinal/hilar nodal or lung tumor tissue sampling
-Suspected mediastinal/hilar lymph nodes or lung tumor within reach of EBUS/ EUS-B
-18 years or older
-Provision of a written consent
Exclusion Criteria
-Mediastinal re-staging after neo-adjuvant treatment
-Contra-indication for EBUS or EUS/B
-Not correctable coagulation disorder
-Pregnancy
-Inability to consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.The suitability rate for the assessment of PD-L1 expression with the EBUS / EUS-B 22 G TBNB novel Boston Acquire?? needle vs 22 G TBNA Boston Scientific BSC standard needle on mediastinal/hilar nodal or tumor aspirates in patients with a final diagnosis of lung cancer.
- Secondary Outcome Measures
Name Time Method